Early inflammatory markers as prognostic indicators following allogeneic stem cell transplantation

Publication
Article

Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation.

Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation.

Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation.

Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation. This study seeks to enhance early prediction of patient outcomes through the monitoring of 92 proteins immediately after transplantation and 2 weeks post-transplantation.

The study found that patients who later developed acute graft versus host disease exhibited lower levels of IL18-R1, LIF-R, and IL22-RA1. Conversely, those who experienced chronic GvHD displayed lower levels of CD244, TSLP, IL15-RA, and IL-33. Higher levels of seven inflammatory proteins—CD244, LIF-R, FGF21, IL10-RB, HGF, CD40, and TNFRSF9—were linked to an increased risk of disease relapse. This underscores the importance of dynamic monitoring of inflammatory responses to better predict and potentially mitigate post-transplant complications.

These findings emphasize the potential role of specific proteins and their receptors in alloreactive immunity and suggest a link between baseline inflammatory profiles and treatment outcomes. The trajectory of change in protein concentrations provides a strong indication of the risk of GvHD or relapse, indicating a strategic approach to patient monitoring that could lead to personalized care. Despite its limitations, such as the need for validation in larger cohorts, this study marks a significant step toward the utilization of early post-transplant biomarkers for predicting clinical outcomes.

Reference

Verma K, Croft W, Greenwood D, et al. Early inflammatory markers as prognostic indicators following allogeneic stem cell transplantation. Front Immunol. 2024;14:1332777. Published 2024 Jan 3.

https://doi.org/10.3389/fimmu.2023.1332777

Recent Videos
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Related Content
Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD

Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD

American Society for Transplantation and Cellular Therapy
September 26th 2024
Article

These findings demonstrate the potential risks associated with CNI-based immunosuppression in stem cell transplantation without concurrent strategies to eliminate alloreactive T cells.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Data from the IMerge trial affirm the enduring responses and clinical benefit with imetelstat in those with transfusion-dependent MDS.

Lower-Risk MDS Population Has Enduring RBC-TI Following Imetelstat Therapy

Ashling Wahner
September 8th 2024
Article

Data from the IMerge trial affirm the enduring responses and clinical benefit with imetelstat in those with transfusion-dependent MDS.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

A ready-to-use subcutaneous or intravenous injection of bortezomib for multiple myeloma and MCL has been approved by the FDA.

FDA Approves Bortezomib Injection in Multiple Myeloma/MCL

Ariana Pelosci
September 6th 2024
Article

A ready-to-use subcutaneous or intravenous injection of bortezomib for multiple myeloma and MCL has been approved by the FDA.

Treatment-Responsive Acute Graft-versus-Host Disease After Post-Transplantation Cyclophosphamide-Based Prophylaxis: Incidence and Clinical Outcomes

Treatment-Responsive Acute Graft-versus-Host Disease After Post-Transplantation Cyclophosphamide-Based Prophylaxis: Incidence and Clinical Outcomes

American Society for Transplantation and Cellular Therapy
August 30th 2024
Article

A recent study investigated the incidence and clinical outcomes of acute graft-versus-host disease following post-transplantation cyclophosphamide-based prophylaxis in hematopoietic cell transplantation.